Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria

Last updated: October 30, 2026
Sponsor: Novartis Pharmaceuticals
Overall Status: Completed

Phase

3

Condition

N/A

Treatment

KLU156

Coartem

Clinical Study ID

NCT05842954
CKLU156A12301
2022-002675-10
  • Ages 2-100
  • All Genders

Study Summary

This study aimed to confirm the efficacy, safety and tolerability of KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF), when administered once daily for three days in adults and children ≥ 10 kg of body weight suffering from uncomplicated P. falciparum malaria (with or without other Plasmodium spp. co-infection).

In the extension phase, the safety, tolerability and efficacy of repeated treatment with KLU156 was assessed for a maximum of approximately 18 months in patients who did not experience early treatment failure (ETF), who did not experience any study treatment-related SAE (Serious Adverse Event) previously and who gave informed consent to participate in the Extension phase.

Eligibility Criteria

Inclusion

Key Inclusion criteria (Core phase)

  1. Male or female patients ≥ 10 kg of body weight.

  2. Microscopically confirmed diagnosis of uncomplicated P. falciparum malaria with an asexual P. falciparum parasitemia ≥ 1,000 and ≤ 200,000 parasites/µL at the time of pre-screening with or without other Plasmodium spp. co-infection.

  3. Axillary temperature ≥ 37.5 ºC or oral temperature ≥ 38.0 ºC or tympanic/rectal temperature ≥ 38.5 ºC; or history of fever during the previous 24 hours (at least documented verbally)

  4. Negative pregnancy test for patients of childbearing potential

  5. Signed informed consent was obtained before any assessment is performed; for minors, signed informed consent was obtained from parent/legal guardian. If the parent/legal guardian was unable to read and write, then a witnessed consent according to local ethical standards was permitted. Patients who were capable of providing assent, must have provided it along with parent/legal guardian consent or as per local ethical standards

  6. The patient and/or their parent/legal guardian was able to understand and comply with protocol requirements, instructions and protocol-stated restrictions and was likely to complete the study as planned.

Key Exclusion criteria (Core phase)

  1. Signs and symptoms of severe malaria according to WHO 2015 (World Health Organization)

  2. Concurrent febrile illnesses (e.g., typhoid fever, known or suspected dengue fever, known COVID19)

  3. Severe malnutrition. For patients ≥ 12 years: body mass index (BMI) < 16.0. For children < 12 years: less than 70% of median normalized WHO reference weight or very low mid-upper arm circumference (MUAC < 115 mm)

  4. Repeated vomiting (defined as > 3 times in the 24 hours prior to start of screening) or severe diarrhea (defined as > 3 watery stools in the 24 hours prior to start of screening)

  5. Clinically relevant abnormalities of electrolyte balance which required correction, e.g., hypokalemia, hypocalcemia or hypomagnesemia

  6. Anemia (hemoglobin level <7 g/dL)

  7. Any surgical or medical condition which might have significantly altered the absorption, distribution, metabolism, or excretion of drugs (e.g., Human immunodeficiency virus (HIV) patients on antiretroviral therapy (ART) or tuberculosis (TB) patients on treatment), or which may have jeopardized the patient in case of participation in the study.

  8. Any of the following:

  • Aspartate Aminotransferase/ Alanine Aminotransferase (AST/ALT) > 3 x the upper limit of normal (ULN), regardless of the level of total bilirubin

  • Total bilirubin > 3 x ULN

  • Resting QT interval corrected by Fridericia's formula (QTcF) > 450 ms at screening

  1. Prior antimalarial therapy or antibiotics with antimalarial activity within minimum of their five plasma half-lives (or within 4 weeks of screening if half-life was unknown)

  2. History or family history of long QT syndrome or sudden cardiac death, or any other clinical condition known to prolong the QTc interval, such as history of symptomatic cardiac arrhythmias, clinically relevant bradycardia or severe heart disease

  3. Pregnant or nursing (lactating) patients.

Study Design

Total Participants: 1720
Treatment Group(s): 2
Primary Treatment: KLU156
Phase: 3
Study Start date:
March 07, 2024
Estimated Completion Date:
November 25, 2025

Study Description

The purpose of this study was to confirm the efficacy, safety and tolerability of KLU156 in patients with uncomplicated P. falciparum malaria (with or without other Plasmodium spp. co-infection) by demonstrating that KLU156 is non-inferior to Coartem.

  • The total study duration was up to approximately 20 months.

  • The treatment duration was 3 days for each malaria episode.

  • The visit frequency was Days 1-3 (hospitalized) and 5 follow-up visits (Days 4, 8, 22, 29 and 43) in the Core phase and Days 1-3 (hospitalized) and 3 follow-up visits (Days 4, 8 and 29) in the Extension phase.

This study had two different primary outcomes depending on the submission (US New Drug Application (NDA) or non-US submissions).

Protocol amendment 01 increased the minimum body weight requirement for study participation from ≥ 5 kg to ≥ 10 kg and revised the statistical analysis plan to exclude patients < 10 kg from the main analyses.

Connect with a study center

  • Novartis Investigative Site

    Banfora,
    Burkina Faso

    Site Not Available

  • Novartis Investigative Site

    Bobo-Dioulasso,
    Burkina Faso

    Site Not Available

  • Novartis Investigative Site

    Nanoro, BP 18
    Burkina Faso

    Site Not Available

  • Novartis Investigative Site

    Ouagadougou,
    Burkina Faso

    Site Not Available

  • Novartis Investigative Site

    Sabou,
    Burkina Faso

    Site Not Available

  • Novartis Investigative Site

    Abidjan, 13 BP 972
    Côte d’Ivoire

    Site Not Available

  • Novartis Investigative Site

    Agboville,
    Côte d’Ivoire

    Site Not Available

  • Novartis Investigative Site

    Azaguié,
    Côte d’Ivoire

    Site Not Available

  • Novartis Investigative Site

    Kimpese, Bas-Congo Province
    Democratic Republic of the Congo

    Site Not Available

  • Novartis Investigative Site

    Kisantu, Bas-Congo Province
    Democratic Republic of the Congo

    Site Not Available

  • Novartis Investigative Site

    Lubumbashi, Du Haut Katanga 7010
    Democratic Republic of the Congo

    Site Not Available

  • Novartis Investigative Site

    Kenge, Kwango
    Democratic Republic of the Congo

    Site Not Available

  • Novartis Investigative Site

    Masi-Manimba, Kwilu
    Democratic Republic of the Congo

    Site Not Available

  • Novartis Investigative Site

    Lambaréné, BP 242
    Gabon

    Site Not Available

  • Novartis Investigative Site

    Libreville, BP 1437
    Gabon

    Site Not Available

  • Novartis Investigative Site

    Kintampo, 92037
    Ghana

    Site Not Available

  • Novartis Investigative Site

    Navrango, VWJ6+8WF
    Ghana

    Site Not Available

  • Novartis Investigative Site

    Kombewa, 40102
    Kenya

    Site Not Available

  • Novartis Investigative Site

    Nairobi, 00200
    Kenya

    Site Not Available

  • Novartis Investigative Site

    Siaya, 2300
    Kenya

    Site Not Available

  • Novartis Investigative Site

    Sotouba,
    Mali

    Site Not Available

  • Novartis Investigative Site

    Niamey, 8003
    Niger

    Site Not Available

  • Novartis Investigative Site

    Gicumbi, Northern Province
    Rwanda

    Site Not Available

  • Novartis Investigative Site

    Kigali,
    Rwanda

    Site Not Available

  • Novartis Investigative Site

    Rubavu,
    Rwanda

    Site Not Available

  • Novartis Investigative Site

    Rusizi,
    Rwanda

    Site Not Available

  • Novartis Investigative Site

    Bagamoyo, 78373
    Tanzania

    Site Not Available

  • Novartis Investigative Site

    Korogwe Tanga, 9653
    Tanzania

    Site Not Available

  • Novartis Investigative Site

    Tanga, 5004
    Tanzania

    Site Not Available

  • Novartis Investigative Site

    Tororo, 10102
    Uganda

    Site Not Available

  • Novartis Investigative Site

    Nchelenge, Luapula Province 70100
    Zambia

    Site Not Available

  • Novartis Investigative Site

    Ndola, 71769
    Zambia

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.